Markets closed

MetLife, Inc.

MET · NYSE

Analyst Consensus

Buy

16 analysts

$98

Current

—

Low

$108

Average

—

High

Average target implies +10.50% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across 16 analysts, with a stated mean price target of $102. The supplied data provide no low or high targets, so the target spread cannot be measured, and no named analyst is identified as most or least bullish. No analyst target revisions are reported for the past week. However, Zacks says MetLife's earnings estimates are rising ahead of second-quarter results. The substantive disagreement is operational rather than target-specific: the bullish case rests on Group Benefits and Retirement & Income Solutions strength producing a beat, while the cautious case centers on investment-income pressure and uncertain commercial pricing and underwriting trends.

Rating Actions

No individual rating actions have been captured for METyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BARCLAYS CAPITA

CITIGROUP

DEUTSCHE BK SEC

DOWLING & PARTN

EVERCORE ISI

GOLDMAN SACHS

JEFFERIES & CO.

JP MORGAN SECUR

KEEFE BRUYETTE

MORGAN STANLEY

PIPER SANDLER

RAYMOND JAMES

UBS

WELLS FARGO SEC

Symbol: MET
Type: Stock
Sector: Finance
Industry: Life Insurance
Exchange: NYSE

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ('MetLife'), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East.

Key Issues

Bullish view

Rising earnings estimates and expected strength in Group Benefits support the case that MetLife can exceed second-quarter expectations.

Bearish view

The supplied evidence only describes expected strength, not an actual result, and a beat could be limited if other businesses fail to contribute.

Analyst Consensus

See all

Buy

16 analysts

$98

Current

—

Low

$108

Average

—

High

Average target implies +10.50% versus the current price.

Earnings History

BeatMissNo estimate

MetLife, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers